- Home
- COP vs SNY Comparison
COP vs SNY Comparison
Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | SNY |
|---|---|---|
| Founded | 1917 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.6B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COP | SNY |
|---|---|---|
| Price | $91.35 | $48.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $115.17 | $61.50 |
| AVG Volume (30 Days) | ★ 7.2M | 2.5M |
| Earning Date | 02-05-2026 | 01-29-2026 |
| Dividend Yield | ★ 3.67% | 3.30% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 7.08 | ★ 8.67 |
| Revenue | ★ $61,280,000,000.00 | $53,890,648,839.00 |
| Revenue This Year | $10.15 | $1.73 |
| Revenue Next Year | N/A | $6.49 |
| P/E Ratio | $12.94 | ★ $10.94 |
| Revenue Growth | ★ 7.65 | N/A |
| 52 Week Low | $79.88 | $44.62 |
| 52 Week High | $106.20 | $60.12 |
Technical Indicators
Market Signals| Indicator | COP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 46.32 |
| Support Level | $91.63 | $48.16 |
| Resistance Level | $94.53 | $48.74 |
| Average True Range (ATR) | 2.17 | 0.64 |
| MACD | -0.35 | 0.05 |
| Stochastic Oscillator | 8.19 | 65.42 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.